Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
Overview | Financials
| Company Name | Atea Pharmaceuticals, Inc. |
| Symbol | AVIR |
| Currency | USD |
| Price | 3.25 |
| Market Cap | 257,912,200 |
| Dividend Yield | 0% |
| 52-week-range | 2.455 - 4.145 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Jean-Pierre Sommadossi Ph.D. |
| Website | https://ateapharma.com |
An error occurred while fetching data.
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD







